256 related articles for article (PubMed ID: 37258037)
1. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series.
Coustal C; Vanoverschelde J; Quantin X; Lesage C; Michot JM; Lappara A; Ederhy S; Assenat E; Faure M; Issa N; Lambotte O; Puyade M; Dereure O; Tosi D; Rullier P; Serre I; Larcher R; Klouche K; Chanques G; Vernhet-Kovacsik H; Faillie JL; Agullo A; Roubille F; Guilpain P; Maria ATJ
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258037
[TBL] [Abstract][Full Text] [Related]
2. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.
Peleg Hasson S; Salwen B; Sivan A; Shamai S; Geva R; Merimsky O; Raphael A; Shmilovich H; Moshkovits Y; Kapusta L; Rozenbaum Z; Wolf I; Laufer-Perl M
Clin Res Cardiol; 2021 Jan; 110(1):50-60. PubMed ID: 32296970
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
4. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
Naqash AR; Moey MYY; Cherie Tan XW; Laharwal M; Hill V; Moka N; Finnigan S; Murray J; Johnson DB; Moslehi JJ; Sharon E
J Clin Oncol; 2022 Oct; 40(29):3439-3452. PubMed ID: 35658474
[TBL] [Abstract][Full Text] [Related]
5. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study.
Xie X; Wang L; Li Y; Xu Y; Wu J; Lin X; Lin W; Mai Q; Chen Z; Zhang J; Xie Z; Qin Y; Liu M; Lu M; Luo B; Zhou C
Front Immunol; 2022; 13():879900. PubMed ID: 35924238
[TBL] [Abstract][Full Text] [Related]
6. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Mahmood SS; Fradley MG; Cohen JV; Nohria A; Reynolds KL; Heinzerling LM; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Awadalla M; Hassan MZO; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Lawrence DP; Groarke JD; Neilan TG
J Am Coll Cardiol; 2018 Apr; 71(16):1755-1764. PubMed ID: 29567210
[TBL] [Abstract][Full Text] [Related]
7. A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies.
Guo CW; Alexander M; Dib Y; Lau PKH; Weppler AM; Au-Yeung G; Lee B; Khoo C; Mooney D; Joshi SB; Creati L; Sandhu S
Eur J Cancer; 2020 Jan; 124():15-24. PubMed ID: 31707280
[TBL] [Abstract][Full Text] [Related]
8. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.
Raschi E; Rossi S; De Giglio A; Fusaroli M; Burgazzi F; Rinaldi R; Potena L
Drug Saf; 2023 Sep; 46(9):819-833. PubMed ID: 37341925
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract][Full Text] [Related]
12. Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice.
Tang X; Li Y; Huang H; Shi R; Shen LT; Qian WL; Yang ZG
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8345-8357. PubMed ID: 37076643
[TBL] [Abstract][Full Text] [Related]
13. [Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].
Prevel R; Colin G; Calès V; Renault PA; Mazieres J
Rev Med Interne; 2020 Apr; 41(4):284-288. PubMed ID: 31983550
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge.
Frascaro F; Bianchi N; Sanguettoli F; Marchini F; Meossi S; Zanarelli L; Tonet E; Serenelli M; Guardigli G; Campo G; Calabrò L; Pavasini R
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137806
[TBL] [Abstract][Full Text] [Related]
15. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
Fenioux C; Abbar B; Boussouar S; Bretagne M; Power JR; Moslehi JJ; Gougis P; Amelin D; Dechartres A; Lehmann LH; Courand PY; Cautela J; Alexandre J; Procureur A; Rozes A; Leonard-Louis S; Qin J; ; Cheynier R; Charmeteau-De Muylder B; Redheuil A; Tubach F; Cadranel J; Milon A; Ederhy S; Similowski T; Johnson DB; Pizzo I; Catalan T; Benveniste O; Hayek SS; Allenbach Y; Rosenzwajg M; Dolladille C; Salem JE
Nat Med; 2023 Dec; 29(12):3100-3110. PubMed ID: 37884625
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer.
Xu L; Xu M; Sun W; Zhang W; Song Z
Invest New Drugs; 2023 Dec; 41(6):816-824. PubMed ID: 37902905
[TBL] [Abstract][Full Text] [Related]
17. Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor-induced Myocarditis.
Cadour F; Cautela J; Rapacchi S; Varoquaux A; Habert P; Arnaud F; Jacquier A; Meilhac A; Paganelli F; Lalevée N; Scemama U; Thuny F
Radiology; 2022 Jun; 303(3):512-521. PubMed ID: 35230185
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
Vicino A; Hottinger AF; Latifyan S; Boughdad S; Becce F; Prior JO; Kuntzer T; Brouland JP; Dunet V; Obeid M; Théaudin M
J Neurol; 2024 Apr; 271(4):1947-1958. PubMed ID: 38141128
[TBL] [Abstract][Full Text] [Related]
19. A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer.
Hu Y; Liu C; Jin S; Yi Z; Wang C; Pan X; Huang H
BMC Pulm Med; 2023 Apr; 23(1):119. PubMed ID: 37060029
[TBL] [Abstract][Full Text] [Related]
20.
Boughdad S; Latifyan S; Fenwick C; Bouchaab H; Suffiotti M; Moslehi JJ; Salem JE; Schaefer N; Nicod-Lalonde M; Costes J; Perreau M; Michielin O; Peters S; Prior JO; Obeid M
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34686542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
